NextPoint Therapeutics, a clinical-stage biotechnology company launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7 axis, today announced the company will present four posters highlighting its B7-H7-targeted oncology pipeline at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, to be held in Chicago, from April 25-30, 2025.

NextPoint's presentations will showcase its advanced therapeutic approaches, including its B7-H7-targeted antibody-drug conjugate (ADC) with proprietary linker technology and B7-H7-CD3 bispecific T cell engager with wide therapeutic window. B7-H7 is upregulated on tumor cells across a wide range of cancers with a very limited normal tissue expression profile. The studies will present preclinical evaluation of these first-in-class candidates across multiple solid tumor types expressing B7-H7, complemented by comprehensive tumor expression analyses that support NextPoint's clinical biomarker strategy for identifying the right patient populations for each B7-H7-directed therapy.

Details of the presentations are as follows:

Title: B7-H7-CD3 bispecific T cell engaging antibodies demonstrate potent anti-tumor activity in B7-H7+ preclinical tumor models

Abstract Number: 1556

Section: 15

Session Date/Time: Monday, April 28, 2025, 9:00 AM - 12:00 PM

Title: Comprehensive analysis of B7-H7/HHLA2 expression in pan-solid tumors and its potential significance in anti-tumor immunity

Abstract Number: 3302

Section: 31

Session Date/Time: Monday, April 28, 2025, 2:00 PM - 5:00 PM

Title: Safety and tolerability of NPX372, a novel B7-H7:CD3 bispecific T cell engaging antibody

Abstract Number: 4354

Section: 20

Session Date/Time: Tuesday, April 29, 2025, 9:00 AM - 12:00 PM

Title: B7-H7 is a novel ADC target for solid tumors and shows potent activity with multiple payload-linker technologies

Abstract Number: 7336

Section: 40

Session Date/Time: Wednesday, April 30, 2025, 9:00 AM - 12:00 PM

About B7-H7

B7-H7 (also known as HHLA2) is a member of the B7 family of immune checkpoint proteins that is overexpressed in multiple solid tumor types and associated with poor prognosis. B7-H7 expression has been shown to contribute to immune evasion, making it an attractive target for novel immunotherapeutic approaches.

About NextPoint Therapeutics

NextPoint is launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis. Our team of proven drug developers is advancing an antibody-drug conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint inhibitor. Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed therapy, so that we can deliver first-in-class therapies to a broad range of cancer patients with B7-H7 upregulation across lines of therapies including those who do not benefit from currently approved ADCs/TCEs and PD-1/L1 inhibitors. To learn more, visit nextpointtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250407625405/en/